Bortezomib: a new player in pre- and post-transplant desensitization?
Several desensitization strategies have been investigated for the reversal of acute antibody-mediated rejection or for the removal of preformed anti-HLA antibodies, with the aim to promote access to renal transplantation. Today, their success appears limited or incomplete. Bortezomib, a selective inhibitor of the 26S proteasome, which is largely used in the treatment of multiple myeloma, could be a novel promising desensitizing agent. Its mechanism of action and preliminary clinical use in renal transplantation is reviewed here.
Lemy
Anne
A
Toungouz
Michel
M
Abramowicz
Daniel
D
D001897:Boronic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D000069286:Bortezomib; D003713:Dendritic Cells / Q000187:drug effects; D003888:Desensitization, Immunologic / Q000379:methods*; D006084:Graft Rejection / Q000517:prevention & control*; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D016030:Kidney Transplantation / Q000276:immunology*; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use*
D001897:Boronic Acids; D006680:HLA Antigens; D007518:Isoantibodies; D016328:NF-kappa B; D011719:Pyrazines; D000069286:Bortezomib